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Abstract
Recent research in the field of bronchial asthma has mainly 
focused on eosinophilic disease phenotype. Several trials 
proved the efficacy and safety profile of eosinophils and 
interleukin (IL)-5 targeting molecules, currently approved 
for severe asthma and available on the market. They include 
mepolizumab and reslizumab, IL-5 blocking molecules, and 
benralizumab, targeting the IL-5 receptor and eliciting a 
NK cell-mediated antibody-dependent cellular cytotoxicity 
against eosinophils. Eosinophilic inflammation represents the 
common pathophysiological background of several conditions, 
providing the rationale for the use of the same biologics 
beyond asthma. Although with different evidence grade, from 
clinical trials to case reports, anti-IL-5 biologics have been 
investigated in eosinophilic granulomatosis with polyangitis, 
allergic bronchopulmonary aspergillosis, chronic eosinophilic 
pneumonia, nasal polyposis, hypereosinophilic syndrome, and 
eosinophilic esophagitis. 
However, non-negligible differences between asthma and other 
eosinophilic diseases, particularly in eosinophils homing (blood 
and/or tissues), target organs and thus clinical features, probably 
account for the different response to the same drug in different 
clinical conditions and highlights the need for tailoring the 
therapeutic approach by modulating the drug dose and/or by 
combination therapy with multiple drugs. 
The optimal safety and tolerability profile of anti-IL-5 drugs 
warrants further and larger experimental and real-life 
investigations, which are needed especially in the field of non-
asthma eosinophilic diseases. 
This review aims at summarizing the rationale for the use 
of biologics in eosinophilic diseases and their mechanisms 
of action. The current efficacy and safety evidence about 
eosinophils and IL-5 targeting molecules in asthma and in 
eosinophilic conditions beyond bronchi is also discussed.
Keywords: ABPA, benralizumab, EGPA, eosinophilic esophagitis, 
eosinophilic inflammation, mepolizumab, reslizumab, severe 
asthma.
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Introduction
During the past 10 years, considerable advances have been 
achieved in understanding the inflammatory background 
of several immune-mediated diseases. In particular, the 
eosinophilic inflammation underlying respiratory and non-
respiratory inflammatory diseases has been extensively 
investigated.1 Bronchial asthma, mostly severe eosinophilic 
and allergic phenotypes, has recently represented a main 
focus of both basic and pharmacological research. As a 
consequence, several new molecules have been conceived 
and explored and some of them are already available on the 
market.2
The new biologic drugs for severe eosinophilic asthma 
are substantially enlarging the treatment options and also 
contributing to a better understanding of the pathophysiologic 
mechanisms targeted by the therapeutic molecules.3 The 
increasing amount of knowledge and evidence in the field has 
paved the way to the potential use of biologics for treating 
eosinophilic inflammation beyond bronchi.
This review aims at summarizing the evidence about safety 
and efficacy of eosinophils and interleukin (IL)-5 targeting 
molecules approved for severe asthma and at exploring 
the published data about the use of the same biologics for 
eosinophilic diseases beyond asthma.
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Methods
A selective search on PubMed and Medline (keywords: 
benralizumab, mepolizumab, reslizumab, anti-IL-5 monoclonal 
antibody, anti-IL-5 receptor monoclonal antibody) was 
carried out, including papers published up to January 2019. 
For severe eosinophilic asthma, we selected original articles, 
randomized clinical trials, and review papers relevant to 
the topic (drug mechanisms, drug safety, and efficacy). For 
eosinophilic diseases other than asthma, any type of article 
relevant to the topic, conducted on human subjects, was 
included.
Targeting Eosinophils: 
pharmacological insights
Anti-IL-5 drug mechanisms and effects
Th2 cells and tissue-resident innate lymphoid cells type 2 
(ILC2s) are the main producers of Th2 cytokines (including 
IL-5, IL-4, and IL-13) responsible for eosinophils proliferation, 
activation, and tissue recruitment. Activated eosinophils induce 
tissue lesions through different pathways, further enhanced by 
other cell types, including mast cells (MCs), basophils, T-helper 
type 1 (Th1) and T-helper type 17 (Th17) T cells, B cells, and 
humoral mediators (antibodies, cytokines).4
IL-5 was first described in mice as a B-cell growth and 
differentiation factor.5,6 Subsequently, evidence in humans 
showed a main effect on eosinophils and to a less lesser 
extent on basophils.7 IL-5 is secreted by Th2 cells, namely 
CD4+ and CD8+ T cells, as well as by ILC2s, B cells, MCs, 
eosinophils, basophils, and epithelial cells.3 IL-5 signalling 
triggers the production of factors, which are essential for 
eosinophil differentiation and inhibit cell apoptosis. IL-5 exerts 
its actions via a specific receptor α-subunit (IL-5Rα), with the 
induction of JAK/STAT, MAPK, and PI-3K pathways, or through 
an IL-13/GM-CSF shared β-subunit receptor; MAPK pathway 
activates NF-kB with subsequent eosinophilic/Th2 cytokines 
production.8,9 From a clinical point of view, eosinophils and 
Th2 players are responsible for several pathophysiological 
mechanisms. The most relevant ones are endothelial cell 
damage, altered repair processes, and induction of fibrosis. In 
bronchial asthma, they lead to airways hyperactivity and wall 
remodelling, which are extremely relevant in poor asthma 
control and exacerbations.3
Mepolizumab and reslizumab are humanized monoclonal 
antibodies (mAb) targeting circulating IL-5 and thus preventing 
IL-5 binding to its receptor (Figure 1). Mepolizumab is an 
IgG1 kappa mAb; reslizumab is a humanized IgG4k mAb with 
high affinity for IL-5.2 Benralizumab is an IgG1 kappa mAb 
targeting the epitope of the α-subunit of the IL-5 receptor (IL-
5Rα) on the eosinophils surface and inhibiting IL-5-mediated 
cell proliferation.2 Moreover, its afucosylated constant (Fc) 
oligosaccharides region increases the affinity to the FcγRIIIa 
receptor on NK cells, basophils, and mast cells and is able to 
recruit them as part of benralizumab mechanism of action 
(Figure 1). Through these effector cells, benralizumab is 
able to induce antibody-dependent cellular cytotoxicity 
(ADCC) against both eosinophils and basophils, executed 
by NK cells and/or macrophages.10 As a consequence, a 
complete depletion of eosinophils in the bone marrow and 
blood within 24 hours after the first administration, and an 
almost complete depletion in sputum and tissues (90% and 
96%, respectively)11 can be observed. In eosinophil-driven 
diseases such as severe asthma, CD34+ and IL-5Rα positive 
eosinophil progenitors have been also recognized in tissue and 
peripheral blood, suggesting the occurrence of extramedullary 
eosinophilopoiesis.12
In the bone marrow, mepolizumab (750 mg IV) significantly 
reduced mature and late immature eosinophils compared to 
placebo, whilst the amount of early eosinophil progenitors did 
not decrease in blood or bone marrow.12,13 This finding could 
be explained by the hypothesis that IL-5 mainly contributes 
to eosinophil proliferation and maturation of relatively late 
progenitors and does not affect the differentiation of early 
progenitors.
A low dose of mepolizumab (100 mg SC) seemed insufficient 
to decrease blood and sputum eosinophil progenitors and 
sputum mature eosinophils,14 whilst a weight-adjusted 
relatively high dose of IV reslizumab attenuated the number 
of early progenitors in a comparable cohort of patients with 
prednisone-dependent severe asthma.15
Figure 1. Overview of anti-IL-5 biologics.
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BAS, basophils; EOS, eosinophils; IL-5 R, IL-5 receptor;  
NK, natural killer cells.
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So far, only one small cohort of four asthmatic patients treated 
with a single dose of benralizumab (1 mg/kg IV) documented 
complete depletion of bone marrow eosinophils and their 
early progenitors. In addition, blood and sputum eosinophils 
dramatically decreased under benralizumab treatment.16 
It is possible that the ADCC-related action of benralizumab 
may account for the different impacts of mepolizumab and 
benralizumab on the amount of bone marrow eosinophils 
and late progenitors.10 However, more evidence is needed 
to understand the true clinical relevance of the different 
mechanisms of action.
Safety concerns
Currently, the role of eosinophils is not yet fully understood 
and their depletion has not been related to any pathology, 
as a consequence of a primary immunodeficiency or IgG-
mediated eosinophil precursor destruction.17 The absence of 
characteristic syndromes in eosinophil-deficient mice supports 
that the potential onset of infections, tumours, autoimmune 
diseases, or neoplasms is unlikely. Available scientific data 
suggest that, in healthy subjects, eosinophils do not play 
a critical homeostatic role. Although long-term studies are 
needed, the published evidence supports a convincing anti-
eosinophils and anti-IL-5 compounds safety profile.
Anti-IL-5 and anti-eosinophils 
monoclonal antibodies for severe 
asthma
A significant oral corticosteroids (OCS) sparing effect and clinical 
improvement under mepolizumab treatment was first described 
in hypereosinophilic syndrome and eosinophilic granulomatosis 
with polyangiitis (EGPA).18 When initially tested on asthmatic 
patients, the drug was not able to achieve the expected 
clinical outcomes, in terms of respiratory function parameters 
(specifically peak expiratory flow [PEF], forced expiratory rate 
in one second [FEV1], and bronchial hyper-responsiveness) 
and exacerbation rate.19,20 An important bias in the selection 
of patients accounted for those negative results, namely an 
improper stratification and recruitment according to blood 
eosinophil levels and asthma severity. Later on, DREAM, MENSA, 
and SIRIUS randomized clinical trials (RCTs) demonstrated a 
significant clinical effect of mepolizumab in asthma control 
and steroid-sparing effect in subjects with blood eosinophils 
>300 cells/μL and refractory asthma.21–23 The MUSCA study also 
demonstrated an important and significant improvement of the 
health-related QoL and in the pre-bronchodilator FEV1 values, 
which was maintained up to the end of the study time frame (24 
weeks).24
A post hoc analysis of DREAM and MENSA studies confirmed the 
relevance of baseline blood eosinophil count as a predictive 
biomarker of clinical efficacy.25 However, a clinically significant 
decrease in exacerbation rate has been highlighted also in 
patients with 150 cells/μL or more at baseline. Those findings 
should be taken into account when selecting potential 
candidates to the treatment. An optimal safety and tolerability 
profile with a stable and long-lasting effect up to 4.5 years was 
demonstrated by COSMOS extension study and even more by 
COLUMBA study.26,27 Interestingly, during the last, a decrease in 
lung function was noted, possibly due to a natural progression 
of asthma or to the reduction of OCS dose.
A recent indirect treatment comparison (ITC) based on 
literature data and Cochrane review showed that in patients 
with similar levels of blood eosinophilia, mepolizumab was 
more effective in reducing clinically significant exacerbations 
and asthma control in comparison with reslizumab and 
benralizumab.28 The indirect comparison design itself entails 
methodological limitations, so it will be important to carry out 
head-to-head studies to define the real superiority of one of 
the competitors over the others.
Mepolizumab subcutaneous injection with a dose of 100 
mg every 4 weeks is registered as a treatment for severe 
eosinophilic asthma.29
Patients with uncontrolled eosinophilic asthma and blood 
eosinophil level >400 cells/μL are eligible to reslizumab, which 
showed a significant improvement of FEV1 and QoL, reduction 
of sputum eosinophil count, and reduction of exacerbation rate 
in RCTs.30,31
Data from a post hoc analysis of two pivotal RCTs showed 
higher benefits of reslizumab as add-on therapy in patients 
with severe asthma, higher blood eosinophilia values and 
chronic sinusitis with nasal polyposis (CRSwNP). The subjects 
treated with reslizumab had a reduction of 83% of the annual 
rate of exacerbations, whilst the overall reduction was 54%.32
An open-label extension trial enrolled 1.051 patients treated 
with intravenous (IV) 3.0 mg/kg reslizumab up to 2 years. This 
mAb confirmed a good safety profile with a long-term clinical 
efficacy and improvement of lung function.33 However, the 
IV-approved administration could represent a limitation in 
a real-life setting, due to the need of a venous access and 
an IV perfusion over 20–50 minutes. In overweight or obese 
subjects, the weight-adjusted dosage could overcome the 
practical limitation mentioned previously, as shown in a 
recent study that compared the response to reslizumab in 10 
patients with OCS-dependent asthma previously treated with 
mepolizumab.15 Reslizumab showed best outcomes compared 
to mepolizumab in airway eosinophilia reduction and asthma 
control. Currently, two phase III RCTs evaluating the efficacy 
of reslizumab SC (ClinicalTrials.gov identifier: NCT02452190 
and NCT02501629) and a phase II–III study on patients with 
steroid-dependent refractory eosinophilic asthma previously 
treated with mepolizumab and subsequently treated with 
IV reslizumab for 4 months (ClinicalTrials.gov identifier: 
NCT02559791) are ongoing. The efficacy of reslizumab was also 
confirmed in a 24-week switch study on patients with severe 
eosinophilic asthma previously treated with omalizumab 
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improvement of exacerbation rate and steroid-sparing effect. 
A potential advantage of benralizumab treatment in clinical 
practice is represented by its schedule – it is administered in 
a prefilled syringe every 4 weeks for the first three doses and 
subsequently every 8 weeks, which is a longer interval than the 
monthly schedule of competitors.28
The ZONDA trial substudy highlighted a greater tissue 
depletion of eosinophils due to benralizumab compared 
to mepolizumab and reslizumab.42 Furthermore, the ADCC 
mechanism could overcome the possibility of immune complex 
formation between IL-5 and mepolizumab or reslizumab, which 
may provide a type of IL-5 reservoir leading to an incomplete 
response to treatments, as reported by some studies.43 
Benralizumab demonstrated a sustained higher improvement 
in FEV1, as showed by the SIROCCO and CALIMA RCTs post 
hoc analysis, even in overweight or obese patients with fixed 
airflow obstruction (FAO).44 In two very recent case reports, 
benralizumab was effective in patients previously treated with 
omalizumab and mepolizumab without clinical response.45,46
A 56-week extension study was recently published on 
patients initially enrolled in the SIROCCO or CALIMA studies. It 
mainly focused on the potential consequences of eosinophils 
depletion. No adverse events, including opportunistic 
infections, were recorded confirming the safety of the drug.47 
Table 1 summarizes the main features of anti-IL-5 drugs for 
severe asthma.
In a recent systematic review, Bourdin and colleagues 
performed a matching-adjusted indirect comparison (MAIC) 
between benralizumab, mepolizumab, and reslizumab.48 
Benralizumab and mepolizumab reduced the overall 
exacerbation rate by 52% and 49%, respectively, in comparison 
without clinical benefits.34 At the end of the study (week 
24), 60% of patients showed a significant improvement of 
asthma control test (ACT) score and experienced no more 
exacerbations. Reslizumab had also shown a steroid-sparing 
effect, with a meaningful decrease of daily dose of OCS, from 
72.4% to 52.0% (p=0.019).
Reslizumab intravenous injection with a weight-adjusted 
concentration of 3 mg/kg is approved for severe eosinophilic 
asthma.35
Phase I and II RCTs including patients with severe eosinophilic 
asthma and blood eosinophils >300 cells/μL, demonstrated 
that benralizumab is able to significantly reduce blood 
eosinophil count, inflammatory biomarkers such as derived 
neurotoxin (EDN) and eosinophil cationic protein (ECP), 
and the exacerbation rate.36–38 A proteomic analysis on 
benralizumab impact showed a significant decrease in the 
expression of genes associated with eosinophils and basophils 
proliferation, such as CLC, IL-5Rα, and PRSS33; immune-
signalling complex genes (FCER1A); G-protein-coupled 
receptor genes (HRH4, ADORA3, P2RY14); and further immune-
related genes (ALOX15 and OLIG2). This modulatory effect of 
gene expression was higher for patients with greater blood 
eosinophilia levels.39
Of note, benralizumab is insensitive to circulating IL-5 levels, 
which can increase during asthma exacerbations (this 
sensitivity limits the effectiveness of the two other anti-IL-5 
agents).40 Through the intense depletion of eosinophils, 
benralizumab is also insensitive to the effect of IL-3 and GM-
CSF, making the response to this drug even more impactful.41 
All these peculiarities allowed for interesting results in 
Table 1. Anti-IL-5 at-a-glance comparison.
Compound Administration 
route
Dosage Ideal patients Main strengths
Benralizumab IgG1k mAb 
against IL-5Rα 
subunit
Subcutaneous Every 4 weeks 
for the first  
three doses, 
then every  
8 weeks
Eosinophilic asthma 
≥300 cells/µL, 
CSwNP, late-onset 
asthma
High affinity for IL-5 
receptor and ADCC 
activity, eosinophils 
sustained tissue 
depletion, improvement 
of pulmonary function 
even in patients with FAO
Mepolizumab IgG1k mAb 
anti-IL-5
Subcutaneous 100 mg every  
4 weeks
Eosinophilic asthma 
≥300 cells/µL, 
CSwNP, late-onset 
asthma
Excellent safety profile, 
demonstrated clinical 
efficacy and steroid 
sparing effect
Reslizumab IgG4k mAb 
anti-IL-5
Intravenous  3 mg kg−1  
every 4 weeks
Eosinophilic asthma 
≥400 cells/µL, 
CSwNP
Personalized dosage, 
clinical efficacy, 
improvement of 
pulmonary function
ADCC, antibody-dependent cell cytotoxicity; CSwNP, chronic sinusitis with nasal polyposis; FAO, fixed airway obstruction;  
IL-5Rα, interleukin-5 receptor α-subunit.
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with placebo (rate ratio [RR] 0.94, 95% CI: 0.78–1.13, n=1524) and 
decreased the percentage of clinically significant and severe 
exacerbations both of 52% (RR 1.00, 95% CI: 0.57–1.75; n=1524). 
In addition, the pre-bronchodilator FEV1 improvement was 
similar. A comparison between benralizumab and reslizumab 
has not been carried out because the patient characteristics 
were too different to obtain a reliable estimate. However, a 
similar effectiveness of benralizumab and reslizumab through 
the indirect analysis was detected. As previously mentioned, 
the study design itself weakens the reported results, to be 
verified by direct comparison studies. The subcutaneous 
administration of Benralizumab is approved for the treatment 
of patients with severe eosinophilic asthma and aged 12 years 
or older.
The biologic drugs revolution: the 
steroid-sparing effect
Since the advent of biological therapies, researchers and 
clinicians have tried to define to what extent these drugs 
reduce the need for OCS in patients with severe refractory 
asthma.
In a recent study by Bleecker and colleagues,49 the OCS dose 
was the most important predictive marker of benralizumab 
efficacy in reduction of exacerbations and FEV1 improvement, 
especially for the blood eosinophil threshold of >300 cells/μL.  
Other predictors of positive response to benralizumab are 
represented by frequent asthma exacerbations, nasal polyposis 
and forced vital capacity (FVC) <65% predicted.
Of note, the OCS-sparing effect was not similar for all the anti-
IL-5 drugs. In the ZONDA study,42 benralizumab significantly 
reduced the median OCS dose from baseline by 75%. In 
particular, patients with blood eosinophils >150 cells/μL were 
on prednisone maintenance treatment for at least 6 months; 
then, they started a period of OCS optimization for up to 
6 weeks including an induction phase, a dose-reduction 
phase and a dose-maintenance phase. The primary endpoint 
was the overall OCS dose reduction from randomization to 
maintenance period (weeks 24–28), and the 100% reduction 
of OCS in patients with optimized OCS dose of 12.5 mg 
prednisone or equivalents was included amongst the 
secondary endpoints. In the SIRIUS study (mepolizumab),14 
eligible patients had at least a 6-month history of prednisone 
treatment and eosinophils counts of >150 cells/μL before 
enrolment (or 300 cells/μL in the previous 12 months). 
Subsequently, patients followed a period of OCS optimization 
treatment. After the start of mepolizumab therapy, the 
reduction phase took place. The primary endpoint of the 
study was the overall reduction of OCS from randomization 
to maintenance period (weeks 20–24). A comparison between 
benralizumab and mepolizumab showed that the benefit in 
OCS reduction seems to be similar (about 50%), whilst the 
number of patients able to discontinue OCS therapy was 
higher for benralizumab compared to mepolizumab (52% and 
14%, respectively; the number needed to treat (NNT) was 3 for 
benralizumab and 17 for mepolizumab).
The greater OCS-sparing effect of benralizumab represents 
a real advantage in the treatment of eosinophilic severe 
refractory asthma, as highlighted by the indirect comparison 
between prednisone-reduction studies (ZONDA-SIRIUS).42,23 
Although head-to-head studies are needed to confirm the 
described trend, the mentioned result could help the clinician 
in identifying the more proper treatment amongst the different 
available options in this field.
Targeting eosinophils besides 
severe asthma: the current 
evidence
Table 2 summarizes the available evidence about the use 
of anti-IL-5 and anti-eosinophil monoclonal antibodies as a 
treatment option for hypereosinophilic conditions other than 
asthma.
Eosinophilic granulomatosis with 
polyangitis
Eosinophilic granulomatosis with polyangiitis is a primary 
small vessel vasculitis characterized by asthma, eosinophilia, 
multiorgan involvement (lung, peripheral nerves, heart, 
gastrointestinal tract, skin), and the possible presence 
(<30% of patients) of anti-neutrophil cytoplasmic antibodies 
(ANCAs).1 Corticosteroids alone represent the traditional 
therapeutic option in the absence of negative prognostic 
factors, whilst cyclophosphamide is recommended for 
severe or corticosteroid-resistant cases. The conventional 
immunosuppressant options also include methotrexate, 
azathioprine, and mycophenolate. Intravenous 
immunoglobulins, IFN-α, infliximab, and rituximab have been 
also used, mainly to target ANCA-associated pathophysiologic 
background, and to a less extent blood and tissue eosinophilia. 
Few data are available concerning omalizumab.50
The supposed key role of eosinophils, and the elevated IL-5 
levels in the inflammatory EGPA background supported 
the rationale for including anti-IL-5 agents amongst the 
treatment options. Kahn and colleagues reported the first 
case documenting the successful use of mepolizumab (750 
mg IV) in a patient with refractory EGPA,51 and experiencing 
improvement in peak flow, decrease blood eosinophils 
count, withdrawal of inhaled treatments during anti-IL-5 
treatment. Before the second infusion, complete regression 
of parenchymal findings was documented at chest-computed 
tomography, which persisted after 6 months. Other small open-
label pilot studies investigated the effect of mepolizumab 
in EGPA patients.52–54 In particular, Moosig and colleagues 
conducted a phase II open-label study, involving 10 patients 
with relapsing/refractory EGPA, who received 9 monthly 
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infusions of mepolizumab (750 mg IV), after stopping previous 
immunosuppressant therapy, and were subsequently switched 
to methotrexate maintenance therapy (0.3 mg/kg/week SC) 
and a tapered dosage of glucocorticoids. This study showed 
disease remission and glucocorticoid daily dose reduction to 
the lowest dose over the course of the disease in almost all 
patients, with no relapses during the active 9-month treatment 
phase. These findings suggested a steroid-sparing effect and 
the potential for induction and maintenance of remission 
in the absence of further conventional immunosuppressive 
treatments.
Recently, the first large-scale multinational RCT on relapsing/
refractory EGPA55 proved the efficacy of anti-IL-5 mAb and 
paved the way to the approval of mepolizumab for this 
condition by the United States Food and Drug Administration. 
Mepolizumab was administered subcutaneously (300 mg) 
every 4 weeks or placebo (68/group) for 1 year, in addition to 
the standard of care treatment. Over a 52 weeks period, 28% of 
patients in the treated group versus 3% in the placebo group 
experienced at least 42 weeks of remission (OR 5.91, 95% CI: 
2.68–13.03; p<0.001), and the percentage of participants in 
remission both at week 36 and week 48 were significantly 
higher in the active group (32 versus 3%; OR 16.74; 95% CI: 
3.61–77.56). Remission was less likely for patients with baseline 
eosinophil counts <150 cells/mm3. Moreover, as a secondary 
endpoint, mepolizumab was able to provide a longer time 
to first relapse within 52 weeks, the reduction of daily 
glucocorticoid dose, a lower circulating eosinophil counts, an 
improved Asthma Control Questionnaire and rhinosinusitis  
22-item Sino nasal Outcome Test score. Conversely, lung 
function did not increase – differently from previous studies on 
severe eosinophilic asthma.2 The most common adverse events 
(AEs) were headache, nasopharyngitis, arthralgia, sinusitis, and 
upper respiratory tract infection. These AEs and their frequency 
were similar in the placebo group. Overall, mepolizumab was 
effective in nearly the 50% of the participants. The reason why 
mepolizumab was ineffective in almost 50% of the patients 
remains unexplained, and further characterization of specific 
EGPA phenotypes, e.g. ANCA-negative versus ANCA-positive 
patients needs to be investigated.50 In fact, a recent genome-
wide association study has confirmed that different genes may 
underlie the complex and diverse potential expressions of 
EGPA in symptoms and clinical subsets.56 With this perspective, 
the investigation of the genetic background may increase in 
accuracy the treatment selection process.
Phase II trials including reslizumab (NCT02947945) and 
benralizumab (NCT03010436) for EGPA are currently ongoing.
Allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is the result 
of a complex hypersensitivity reaction to Aspergillus fumigatus 
(A. fumigatus), characterized by asthmatic symptoms, systemic 
and airway eosinophilia, elevated serum immunoglobulin E 
(IgE) levels, lung infiltration, bronchiectasis, bronchial mucoid 
impaction, and lung fibrosis. The current treatment includes 
the long-term use of oral corticosteroids, in addition to 
antifungal agents, which is potentially associated with serious 
side effects.57 Some evidence supports the potential efficacy 
of omalizumab due to its IgE-blocking activity.58 Although 
the pathophysiology of this condition is not fully understood, 
a pivotal role is played by an impaired innate and adaptive 
immune response, which is not able to clear inhaled fungal 
spores from their respiratory epithelium and sustains an 
intense Th2 inflammation. Innate immunity response to A. 
fumigatus in the lung recruits and activates Th2 cells, leading 
to IL-4 and IL-5 production, and driving the differentiation of 
IgE-secreting plasma cells, as well as recruitment and activation 
of eosinophils. These mechanisms suggest that both IgE and 
IL5 may represent potential treatment targets in patients 
affected by ABPA. As clinical trials on mepolizumab excluded 
ABPA patients, the efficacy of mepolizumab in ABPA remains 
basically unknown. To the best of our knowledge, four case 
reports of ABPA treated with mepolizumab have been reported 
in the literature. In 2018,59 a case report was published of a 
patient with ABPA previously treated with omalizumab (600 mg 
Q2W) with poor response (no improvements on radiological 
findings and eosinophilic sinusitis/otitis media). The patient was 
switched to mepolizumab (100 mg SC Q4W) with subsequent 
resolution of asthmatic symptoms, normalization of blood 
eosinophils and serum IgE value, improvement of radiological 
findings. No improvement of FEV1 was observed.
Another case report described the synergistic and steroid 
sparing effect of omalizumab plus mepolizumab combination 
therapy in a patient showing poor disease control when treated 
with omalizumab only.60
In two further cases,61,62 mepolizumab use in addition to 
standard therapy, resulted in symptoms and FEV1 improvement, 
and in the reduction of ABPA-associated mucoid impaction and 
lung infiltration. The role of IL-5-induced inflammation in the 
pathogenesis and maintenance of symptoms in patients with 
ABPA seems predominant in most cases, independently of IgE 
levels, especially in patients with corticosteroid-dependent 
severe asthma, with suppressed serum IgE levels.58
Recently, Soeda and colleagues63 reported a case series 
including two patients with uncontrolled severe asthma and 
ABPA on long-term treatment with mepolizumab (100 mg 
SC). Blood eosinophilia reduction, symptoms (cough and 
sputum) improvement, FEV1 increase, and radiological findings 
resolution were observed. ACT score significantly increased 
in one case only. The same author in 2018 reported the case 
of a patient affected by ABPA-serologic (ABPA-s), without 
bronchiectasis and/or fibrosis, treated with benralizumab.64  
The drug was well tolerated and rapidly (over 2 months) 
provided symptoms improvement and radiological remission.
Chronic eosinophilic pneumonia
Chronic eosinophilic pneumonia (CEP) is an inflammatory 
disease of unknown aetiology characterized by eosinophilic 
Caminati M, Menzella F, Guidolin L, Senna G. Drugs in Context 2019; 8: 212587. DOI: 10.7573/dic.212587 9 of 15
ISSN: 1740-4398
REVIEW – IL-5 biologics for asthma and other eosinophilic conditions drugsincontext.com
infiltration in the lung. The typical symptoms include cough 
and increasing dyspnea.65 For the treatment of CEP, systemic 
corticosteroid therapy is recommended, and the clinical 
response to corticosteroids is usually very good. However, 
approximately 50% of patients with CEP relapse after cessation 
of steroids treatment or during tapering.65 Only one case of CEP 
successfully treated with mepolizumab has been reported.66
Chronic rhinosinusitis with nasal polyposis
Chronic rhinosinusitis (CRS) is a clinical syndrome with multiple 
phenotypes. The presence of polyps is usually associated 
with local Th2 inflammation, increased eosinophils levels, 
and elevated IL-5 and IgE.67 Non-eosinophilic inflammation 
sustained by Th1 and Th17 pathways may also be observed in 
CRSwNP.68 CRSwNP is often part of a late-onset eosinophilic 
asthma, representing a most relevant comorbidity.
Current treatment options for patients with NP, based on 
the 2016 International Consensus Statement on Allergy and 
Rhinology, include nasal saline irrigations and intranasal 
corticosteroid sprays for maintenance therapy and systemic 
corticosteroids with antibiotics for acute exacerbations. 
For refractory cases, endoscopic sinus surgery should be 
considered.69,70 The underlying eosinophilic inflammation 
provided the rationale for investigating the effect of new 
therapeutic approaches aimed at blocking IL-5 in CRSwNP.
Gevaert and colleagues conducted two randomized, 
double-blind, placebo-controlled trial studies71,72 on the 
safety and efficacy of mepolizumab and reslizumab in 
patients with CRSwNP refractory to endoscopic surgery. 
A statistically significant improvement in nasal symptoms 
and nasal polyp score (NPS) was recorded in both studies, 
whilst only mepolizumab treatment positively impacted 
on CT score. In the mepolizumab study, when divided 
into allergic (n=7) and non-allergic (n=8) responders, CT 
score significantly decreased in the allergic group, but the 
validated Asthma Quality of Life Questionnaire (AQLQ) 
decreased significantly in the non-allergic group. As expected, 
individuals with high serum IL-5 levels had more benefit from 
blocking IL-5.
The effects of two different reslizumab regimens, 1 mg/
kg and 3 mg/kg, were also investigated.71 Amongst the 
eight patients receiving a 1 mg/kg infusion, five subjects 
experienced a significant improvement in Total Nasal 
Polyp Score (TPS) for up to 12 weeks. Half of the patients 
who received a 3 mg/kg infusion maintained a reduction 
in TPS for 4 weeks. Elevated local nasal IL-5 levels at baseline 
versus systemic levels were predictive of a positive response 
to reslizumab.
Mepolizumab efficacy in NP refractory to surgery was more 
recently explored in a larger randomized clinical trial.73 
This involved 105 patients of whom 54 were treated with 
mepolizumab (monthly infusion 750 mg IV) and 51 were 
randomly assigned to the placebo group for a total of six doses 
in addition to daily topical corticosteroids. Nasal symptoms and 
NPS significantly improved, and a reduced need for surgery was 
reported at the end of the 25 weeks period. Of note, there was no 
reactive eosinophilia, which has been observed with reslizumab.
Oda and colleagues74 reported the case of a patient with 
ABPA and CRSwNP treated with mepolizumab at the 
dose of 100 mg Q4W without significant benefit on the 
nasal component, despite reductions in eosinophilia. 
This finding suggests that the high-dose approach used 
by Gevaert and colleagues is needed to properly target 
the amount of eosinophils underlying the nasal polyps 
inflammation.
A phase II (ClinicalTrials.gov Identifier: NCT03450083) and 
a phase III (ClinicalTrials.gov Identifier: NCT03627286) 
randomized, placebo-controlled trials are currently ongoing 
to evaluate the efficacy of benralizumab on eosinophilic 
rhinosinusitis.
Hypereosinophilic syndrome
Hypereosinophilic syndrome (HES) includes different 
disorders characterized by a large amount of eosinophils 
in the blood and/or tissues. Idiopathic hypereosinophilic 
syndrome (IHES) is characterized by elevated levels of 
blood eosinophils (>1500 eosinophils/μL) and by the 
involvement of multiple organs as well as tissue-specific 
disorders such as eosinophilic esophagitis (EoE).75
So far, two preliminary studies investigated the effect of 
mepolizumab in patients affected by both IHES and EoE.  
The former76 evaluated three monthly infusions of 
mepolizumab (10 mg/kg or 750 mg IV) in four patients with 
HES and reported a significant improvement in symptoms 
and QoL in all patients. A FEV1 increase and blood eosinophil 
count decrease were also observed at the 8 weeks follow-up 
assessment.
The latter study was a multicentre, randomized, double-blind, 
placebo-controlled trial carried out on 85 patients treated 
monthly with 750 mg IV of mepolizumab for up to 36 weeks.77 
It described a reduction of prednisone dose to ≤10 mg without 
clinical flare-up in 84% of active group versus 43% placebo 
(p<0.0001), showing a potential glucocorticoid-sparing effect of 
this biologic treatment.
Eosinophilic esophagitis
A predominant infiltration of eosinophils in the oesophageal 
tract underlies EoE, a chronic immune-mediated disease 
presenting with peculiar endoscopic and histologic 
abnormalities. Several eosinophil-derived products cause 
barrier dysfunction, which leads to nonspecific gastrointestinal 
symptoms.78
The 2017 European guidelines indicate as first-line treatment 
proton pump inhibitors (PPIs). Other options include topical 
corticosteroids, elimination or restriction diet, and oesophageal 
Caminati M, Menzella F, Guidolin L, Senna G. Drugs in Context 2019; 8: 212587. DOI: 10.7573/dic.212587 10 of 15
ISSN: 1740-4398
REVIEW – IL-5 biologics for asthma and other eosinophilic conditions drugsincontext.com
dilation, the last related to long-term safety concerns and 
potential complications.79,80
An open-label phase I/II study involving four adult patients 
over 28 weeks81 firstly investigated mepolizumab for EoE at the 
dose of 750 mg intravenously monthly. The main observations 
were a significant decrease in mean and maximal oesophageal 
eosinophilia (p<0.001, p<0.05, respectively), better clinical 
control and improved quality of life (p=0.03) with respect to the 
baseline values. Of note, responsiveness to anti-IL-5 therapy did 
not correlate with plasma IL-5 levels.
More recently, the efficacy of a different mepolizumab schedule 
(750 mg IV, 2 doses 1 week apart, repeated after 8 weeks with 4 
weeks interval between each dose if complete remission was not 
achieved – <5 peak eosinophil number/hpf) was explored in a 
randomized, double-blind, placebo-controlled trial including 11 
patients.82 A significant reduction of tissue eosinophilia and of the 
expression of molecules associated with oesophageal remodelling 
(TGF-β) was observed 4 weeks after the first mepolizumab 
administration, without further improvement compared with the 
placebo group. Nevertheless, a minimal clinical improvement was 
achieved. No safety issues were recorded.
A larger multicentre, randomized, placebo-controlled trial83 
carried out on 59 children (2–17 years old) investigated the 
impact of three monthly infusions of mepolizumab (0.55, 2.5, 
or 10 mg/kg) or placebo, and reported negligible improvement 
in symptoms, remission (only less than 10% of subjects), and 
reduction of tissue eosinophil count <20 hpf (only 31.6% of 
subjects) compared with the placebo group.
Reslizumab has also been evaluated as a treatment option for 
EoE. Spergel and colleagues84 conducted a multicentre RCT 
including 226 subjects randomly assigned to 1, 2, or 3 mg/kg 
of reslizumab. No significant differences in physician s’ global 
assessment scores were recorded between the active and 
placebo groups, independently of the treatment dose and 
oesophageal eosinophil counts. A recent open-label 9-year-
long study was conducted by Markowitz and colleagues85 as 
an extended-access program of RCT mentioned previously. It 
explored treatment at the dose of 2  mg/kg in 12 children and 
adolescents. The authors reported a significant decrease in 
reduction in peak oesophageal eosinophilic count in treated 
patients compared to control groups (67 versus 24% had a 
reduction in peak oesophageal eosinophilic counts to <5 hpf). 
Nevertheless, no difference in symptoms between reslizumab 
and control groups was seen. However, the positive impact 
on tissue eosinophilia and on relapse or disease progression 
documented by endoscopy under therapy, as well as an optimal 
safety profile, paves the way to larger longitudinal studies.
Conclusions
Recent basic and pharmacological research has specifically 
addressed the Th2 high inflammation phenotype, leading 
to the development of new biologic drugs, especially in the 
field of severe eosinophilic asthma. Eosinophilic inflammation 
represents the common pathophysiological background of 
several conditions, providing the rationale for the use  
of the same therapeutic molecules beyond asthma.  
However, non-negligible differences between asthma and 
other eosinophilic diseases occur, particularly regarding 
eosinophils homing (blood and/or tissues), target organs and 
thus clinical expression. Furthermore, despite the increasing 
knowledge and evidence in the field, some issues are still 
under debate.
The correlation between tissue and blood eosinophilia, as 
well as their specific clinical relevance, is not completely clear. 
In addition, the observed discrepancy between known Th2 
biomarkers and clinical response under biologic treatment 
suggests that the underlying inflammatory pathways may 
be much more complex than expected and targeting one 
mechanism may not be enough. This variability probably 
accounts for the different response to the same drug in 
different clinical conditions and highlights the need for 
tailoring the therapeutic approach by modulating the drug 
dose and/or a multiple-treatments association.
Few data are currently available about the long-term 
management of anti-IL-5 drugs in treatment duration, tapering, 
or withdrawal. In fact, whether biologics exert a disease-
modifying effect or their action is limited to the ongoing 
treatment is still controversial.2,3
The clinical relevance of anti-IL-5 tapering has been investigated 
in a small study comparing the effect of the  
fixed dose of mepolizumab and the weight-adjusted  
dose of reslizumab.86 The reported results suggest the 
superiority of the latter particularly in the prednisone-dependent 
asthma phenotype with elevated sputum eosinophilia. 
The available evidence is not sufficient to support practical 
recommendations; however, dose adjustment may represent 
a strategy for management of poor responders. Of note, the 
approved mepolizumab dose for patients with eosinophilic 
granulomatosis is 300 mg every 4 weeks.55 It supports the 
hypothesis that an adjusted mepolizumab dose could be 
considered in difficult-to-treat patients with a more severe 
eosinophilic asthma phenotype or with specific comorbidities.
Conversely, especially in the field of severe asthma, the 
need for biologic therapy continuation should be carefully 
evaluated in light of the overall adherence to anti-asthmatic 
treatments, which is known to be suboptimal.87,88 Biologic 
drugs are currently intended as add-on options; thus, once 
disease control has been achieved and oral corticosteroids are 
no longer needed, if poor adherence to inhaled medications 
occurs the biologic drug should be withdrawn for clinical and 
sustainability reasons.
However, the optimal safety and tolerability profile of  
anti-IL-5 drugs needs to be established in further and  
larger experimental and real-life investigations, which are 
needed especially in the field of non-asthma eosinophilic 
diseases.
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